摘要
目的观察长期吸入福莫特罗/布地奈德治疗稳定期慢性阻塞性肺部疾病(COPD)的疗效。方法对94例稳定期COPD患者进行随机分为4组:A组:吸入福莫特罗/布地奈德,B组吸入沙莫特罗/氟地卡松,C组口服茶碱类缓释剂或长效茶碱类药物,D组不用任何药物。治疗1年。评估肺功能(FEV1,FEV1/FVC)、AECOPD情况及治疗满意度。疗效比较采用优势检验。结果94例全部完成1年随访,吸入福莫特罗/布地奈德组和吸入沙莫特罗/氟地卡松组明显减缓肺功能的恶化,明显减少AECOPD的次数及延迟首次AECOPD时间;同时发现吸入福莫特罗/布地奈德组较其他三组有着明显的较好治疗满意度。结论吸入福莫特罗/布地奈德由于起效快且持续时间长,在改善症状方面优于吸入沙莫特罗/氟地卡松,具有较好的依从性。
Objective To observe the benefits of maintenance therapy with inhaling of budesonide and formoterul in stable chronic obstructive pulmonary disease. Methods This was a randomized, parallei-group, placebo-controlled clinical trial. The trial was conducted in 94 patients with stable chronic obstructive pulmonary disease. They were randomized into inhaling of budesonide/formoteroland salmeterol/flutieasone, oraling of slow-release theophylline （ 200 mg bid ） , placebo （ not at all）, for one year. Efficacy measures were spirometry and exacerbateions, satisfaction with treatments. Comparison of benefits was performed using superiority test. Results Of 94 patfents, all eompleted the study. The analysis showed that groups with the treatment of inhaling of budesonide/formoterol and salmeteroL/ fluticasone statistically slower descent of FEVI than the groups of slow-release theophylline and placebo. And the groups with the treatment of inhaling of budesonide/formoterol and salmeteroL/fluticasone experienced statistically fewer numbers than the groups of slow-release the- ophylline and placebo. And times to the first exacerbateion in patients receiving the treatment of inhaling of budesonide/formoterol was also delayed in comparison to the groups of slow-release theophylline and placebo. And the individuals were more satisfied with treatment in the inhaling of budesonide/formoterol than that in the others. Conclusion inhaling of budesonide/formoterol may be beneficial and had better compliance in long - term treatment of stable COPD.
出处
《临床肺科杂志》
2007年第11期1164-1166,共3页
Journal of Clinical Pulmonary Medicine
